Egypt: Ever Art crosses Suez Canal on its first voyage    IFC loans Egypt's El Sewedy $150 million for more access to renewable energy in Africa    Gold prices in Egypt on June 29    Saudi citizens could enter Schengen countries visa-free    Egypt's Petrojet returns to Libyan oil sector after 11 years    Cemex, VeryNile sign deal for Egypt's Nile River    NATO remarks Egypt's role in maintaining stability in Middle East and Africa    Congo needs Egypt's expertise to diversify its economy – FPI official    Dostarlimab drug cures rectal cancer patient 100%, trials show    Egypt: A royal train turns into a new tourism attraction    Conclusions and Recommendations of the 1st edition of Africa Health ExCon    For the first time John Legend to perform in Egypt    Egypt discovers newly treasure trove of ancient artifacts at Saqqara Necropolis    Noura Al-Mutair – first Gulf female boxer in World Championships    Liverpool fans: "You'll Never Walk Alone" to Cristiano Ronaldo    Egypt to play key role in integrating water, climate issues globally – World Bank official    Egypt's telecoms regulator announces working hours for holy month of Ramadan    Maha karara joins AAIB as Head of Corporate Communications, Sustainability    Egypt works on charting cooperation strategies with international institutions for 5 years: Al-Mashat    Over 2.4 million newborns examined for hearing impairment: Health Ministry    Netflix releases trailer of Arab adaption of 'Perfect Strangers' film    Balqees to headline concert celebrating launch of streaming giant LIVENow in MENA    Sawsan Badr to be honoured at Aswan Women Film Festival    MP Abdel Hady Al-Qasby calls government to facilitate and support NGOs    Al-Sisi follows up on 'Great Transfiguration Project' in St. Catherine    Cairo, London stress need to strengthen cooperation to face climate change    Foreigners account for 22.6% of Egypt's T-bills issuances in 1H 2021: CBE    Egypt's ambassador to Italy passes away    Egypt confirms readiness to help African countries face terrorism and extremism    An estimated 235 million people needed humanitarian assistance and protection in 2021, an increase of 40% compared to 2020: IOM Egypt    Egypt, DRC discuss water cooperation during WYF    Egypt, DR Congo discuss boosting bilateral cooperation during WYF    Cameroonian police probe assault on three Algerian journalists covering AFCON    Pharaohs start AFCON 2021 campaign with fierce clash against Nigeria    Foreign Ministry opens capacity building course for French-speaking African diplomats    Egypt's trade with Nile basin countries climbs 26% y-o-y in 9 months    Russia says it's in sync with US, China, Pakistan on Taliban    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    

Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.

Why is the EU taking so long to OK vaccine?
Published in Ahram Online on 15 - 12 - 2020

As Canadians, Britons and Americans begin getting immunized with a German-developed vaccine against coronavirus, pressure is building on the European Medicines Agency to approve the shot made by Pfizer Inc. and the German company BioNTech. German officials have been especially vocal that they want it approved before Christmas. Here's a look at the EMA approval process:
The EMA is Europe's medicines regulatory agency and approves new treatments and vaccines for all 27 countries across the European Union. It is roughly comparable to the U.S. Food and Drug Administration. The agency is headquartered in Amsterdam and it has nearly 900 employees.
Britain, Canada and the U.S. granted approval for the Pfizer-BioNTech vaccine to be used under emergency use provisions earlier this month, meaning the shot is an unlicensed product whose temporary use is justified by the urgency of a pandemic that has already killed over 1.6 million people.
But the EMA's approval process for coronavirus vaccines is largely similar to the standard licensing procedure that would be granted to any new vaccine, only on an accelerated schedule. The companies will still need to submit follow-up data to the EU regulator and the approval will need to be renewed after one year.
EMA Executive Director Emer Cooke told The Associated Press that while all of the regulatory agencies in the U.S., Britain and Canada are largely looking at the same data, ``we may not have all gotten it at the same time.'' EMA began its expedited approval process of the Pfizer-BioNTech vaccine in October and the companies formally asked for their shot to be licensed on Dec. 1.
Using its expedited approval process, the EMA says the time for assessing a new drug or vaccine has been shortened from about 210 days to fewer than 150.
The EMA is convening an ``extraordinary'' meeting on Dec. 29 _ although that date could be moved up sooner _ during which their experts will discuss the data behind the Pfizer-BioNTech vaccine. The meeting, which will be closed, will include a presentation by two officials charged with assessing the vaccine and could also include bringing in company representatives to answer questions.
Within hours of the meeting's conclusion, the EMA will issue a statement on whether or not it is recommending the vaccine be approved. Several days later, they will release their full scientific assessment explaining the decision.
The EMA's approval is valid in all 27 EU countries and once it is granted, countries can start receiving vaccines for immunization campaigns. An Italian health official says all EU countries want to start vaccinations on the same day.
Germany is increasing the pressure on the agency, with its health minister, a leading hospital association and lawmakers all demanding that it approve a coronavirus vaccine before Christmas.
``Our goal is an approval before Christmas so that we can still start vaccinating this year,'' Health Minister Jens Spahn said.
Spahn has expressed impatience with the EMA, noting that Germany has already created some 440 vaccination centers, activated about 10,000 doctors and medical staff and was ready to start mass vaccinations.
The German Hospital Association chipped in Tuesday as well, demanding that the agency issue emergency authorization for the Pfizer-BioNTech vaccine. That way, it says, workers can go into nursing homes to vaccinate those most at risk of dying from the virus.
Other EU nations are also getting impatient.
``My hope is that the EMA, in compliance with all safety procedures, will be able to approve the Pfizer-BioNTech vaccine earlier than expected and that vaccinations can also begin in the countries of the European Union as soon as possible,'' Italian Health Minister Roberto Speranza said Tuesday.
Cooke, the agency's chief, said Monday that EMA staff are working ``around the clock'' and that if they have sufficient data and have completed their required protocols, the Dec. 29 meeting to consider the Pfizer-BioNTech vaccine could indeed be moved up.
``We feel a huge responsibility to get this right ... to make sure that what we deliver in terms of a scientific opinion is robust and reliable,'' Cooke told the AP in an interview last week. ``It's already a huge responsibility, I can tell you, without putting a race around it.''
The EMA is also planning to convene a meeting Jan. 12 to consider approving the coronavirus vaccine made by Moderna, but said that discussion too could be moved up earlier.
It is also assessing data from two other vaccines, one made by Oxford University and AstraZeneca and the other by Janssen, but neither of those two companies have yet made a formal request to be licensed in the EU.
The agency usually asks companies to deliver data on vaccines' safety and side effects every six months, but due to the coronavirus pandemic, it will be asking companies for that data every month.
``We need to consider how (these vaccines) perform once they are once they are deployed in a mass vaccination situation,'' Cooke said, explaining that the EMA is adopting extra surveillance measures to detect any rare or serious side effects.
Although tests of the Pfizer-BioNTech vaccine suggested the shot is safe and about 95% effective in preventing COVID-19, there is still limited long-term safety data on it.
On the day that Britain started its mass vaccination program last week, severe allergic reactions were reported in two people who got the shot. Officials are now investigating if those reactions were caused by the vaccine and have advised people with severe allergies not to get the shot.

Clic here to read the story from its source.